Markets
Madrigal Stock Soars 9%, Adding $885 Million, After First Profitable Quarter
The Rezdiffra maker posted $55.4 million in profit on $431.3 million in drug sales, and a second cirrhosis trial is planned.
MDGL
Madrigal Pharmaceuticals (MDGL) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
Madrigal Faces Whistleblower Retaliation Suit Just As Rezdiffra Delivers First Profitable Quarter
A former employee alleges retaliation after raising data concerns; Madrigal earned $55.4 million in the quarter and says it will fight the suit.
SEC Filings
Madrigal Posts $55.4 Million Quarterly Profit As Rezdiffra Sales Climb 50% To $431.3 Million
The MASH drugmaker says it reached its first profitable quarter, with Rezdiffra year-to-date sales of $1.1 billion.
Earnings
Madrigal Plans A 2,000-Patient Cirrhosis Trial, Saying It's What 'Leaders In A Space' Do
CEO Bill Sibold defended a second outcomes trial on the earnings call and pointed to late 2027 for the first trial's readout.